Inclusion Criteria:

1. Patients who have a diagnosis of supratentorial glioblastoma or gliosarcoma by
pathology review after initial tumor resection and who have radiographic evidence of
recurrent tumor.

2. Eligibility will be restricted to patients in whom the clinical decision has been
made to perform surgery at recurrence for symptom relief or for cytoreduction. Due to
the requirement that SCH 900105 treatment will be given for 15 days prior to surgery,
only patients who are determined to be not at risk from this delay in the best
clinical judgment of the neurosurgeon, the treating neuro-oncologist and the study
chair will be eligible for entry into the study.

3. (2. continued) Patients who are in poor clinical condition as defined by Karnofsky
performance status (KPS) or have progressive symptoms necessitating urgent surgery
will be excluded from this study.

4. Patients must have enhancing disease on the MRI scan sufficient to provide tissue
samples for pathological diagnosis & correlative studies AND if the surgical plan
includes resection of this part of the tumor. Patients with radiologically evident
areas of tumor necrosis will be eligible for entry into this study if there is
sufficient non-necrotic tumor to permit tissue correlative studies. The study chair
will make a determination with the help of the treating physician, neuro-radiologist
and neurosurgeon whether a particular patient fulfils the radiological requirements
for study entry.

5. Patients must have failed prior radiation therapy and must have an interval of
greater than or equal to 12 weeks (84 Days) from the completion of radiation therapy
to study entry.

6. Patients may have had treatment for no more than 3 prior relapses. Relapse is defined
as progression following initial therapy (i.e. radiation +/- chemo if that was used
as initial therapy). The intent therefore is that patients had no more than 4 prior
therapies (initial and treatment for 3 relapses). For patients who had prior therapy
for a low-grade glioma, a prior surgical diagnosis of a high-grade glioma will be
considered the first relapse.

7. Patients must have recovered from the toxic effects of prior therapy at the time of
initiation of the study drug: 4 weeks from any investigational agents, two weeks from
vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, 3
weeks for temozolomide, 4 weeks for carboplatin, and 1 week for non-cytotoxic agents,
e.g., interferon, tamoxifen, cis-retinoic acid, etc. (radiosensitizer does not
count). Prior anti-angiogenic therapy is not allowed. For patients who have undergone
radiation therapy (XRT), at least 12 weeks should have elapsed since completion of
XRT.

8. Patients must be equal to or greater than 18 years of age.

9. All patients must sign an informed consent indicating that they are aware of the
investigational nature of this study. Patients must have signed an authorization for
the release of their protected health information.

10. Patients must have adequate bone marrow function (absolute granulocyte count >/=
1,500 and platelet count >/= 100,000), normal coagulation profile (PT/PTT), adequate
liver function (SGPT, SGOT, and alkaline phosphatase bilirubin < 1.5 mg/dL), adequate renal function (BUN or creatinine institutional normal) and institutional normal serum amylase within 14 days prior to
starting therapy.

11. Patients must have a Karnofsky performance status (KPS) of >/= 60.

12. All patients (men and women) of childbearing potential must agree to use adequate
birth control (barrier methods) during and for 1 month after participation in this
study.

13. Women of childbearing potential must have a negative Beta Human Chorionic
Gonadotropin(B-HCG) pregnancy test documented within 14 days prior to registration.

14. This study was designed to include women and minorities, but was not designed to
measure differences of intervention effects. Males and females will be recruited with
no preference to gender.

15. Archived paraffin embedded tissue (15 unstained slides) must be available for
confirmation of tumor diagnosis and correlative studies prior to receiving the first
dose of SCH 900105.

Exclusion Criteria:

1. Patients who have been previously treated with c-Met inhibitors are ineligible for
this study.

2. Patients must not have any significant medical illnesses that in the investigator's
opinion cannot be adequately controlled with appropriate therapy or would compromise
the patient's ability to tolerate this therapy.

3. Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
for that disease for a minimum of 3 years are ineligible.

4. Patients must not have active infection or with a fever >/= 38.5°C within 3 days
prior to the first dose of SCH 900105.

5. Patients must not be pregnant/breast feeding during and for 1 month after
participation in this study.

6. Patients must not have any disease that will obscure toxicity or dangerously alter
drug metabolism.

7. Patients on full-dose anticoagulants (e.g., warfarin, low molecular weight heparin)
for the treatment of deep vein thrombosis(DVT), pulmonary emboli (PE), atrial
fibrillation, myocardial infarction, or any other thromboembolic event are not
eligible.

8. No exclusion to this study will be based on race. Minorities will actively be
recruited to participate. The malignant glioma patient population treated at MDACC
over the past year is as follows: American Indian or Alaskan Native - 0; Asian or
Pacific Islander - <2%; Black, not of Hispanic Origin - 3%; Hispanic - 6%; White, not
of Hispanic Origin - 88%; Other or Unknown - 2%; Total - 100%

9. The safety profile of SCH 900105 was not established in the pediatric population,
Patients under age 18 will be excluded.